Page 43 - Read Online

Page 12 of 13 Briggs et al. J Cancer Metastasis Treat 2021;7:46 https://dx.doi.org/10.20517/2394-4722.2021.84

18. Beuselinck B, Vano YA, Oudard S, et al. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell
carcinoma (RCC) treated with sunitinib. BJU Int 2014;114:81-9. DOI PubMed
19. Tornberg SV, Nisen H, Järvinen P, et al. Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma.
Scand J Urol 2020;54:413-9. DOI PubMed
20. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase
III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8. DOI PubMed
21. Chamie K, Klöpfer P, Bevan P, et al. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-
risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol Oncol 2015;33:204.e25-33. DOI
PubMed
22. Dias F, Lu A, Morais M. Plasma extracellular vesicle-derived TIMP-1 mRNA as a prognostic biomarker in clear cell renal cell
carcinoma: a pilot study. Int J Mol Sci 2020;21:4624. DOI PubMed PMC
23. Carlo MI, Manley B, Patil S, et al. Genomic alterations and outcomes with VEGF-targeted therapy in patients with clear cell renal cell
carcinoma. Kidney Cancer 2017;1:49-56. DOI PubMed PMC
24. Linehan WM, Spellman PT, Ricketts CJ, et al; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of
papillary renal-cell carcinoma. N Engl J Med 2016;374:135-45. DOI PubMed PMC
25. Braun DA, Hou Y, Bakouny Z, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in
advanced clear cell renal cell carcinoma. Nat Med 2020;26:909-18. DOI PubMed PMC
26. Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Burden of tumor mutations, neoepitopes, and other variants are weak
predictors of cancer immunotherapy response and overall survival. Genome Med 2020;12:33. DOI PubMed PMC
27. Motzer RJ, Choueiri TK, Mcdermott DF, et al. Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus
ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). JCO 2020;38:5009-5009. DOI
28. Motzer RJ, Robbins PB, Powles T, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis
of the phase 3 JAVELIN Renal 101 trial. Nat Med 2020;26:1733-41. DOI PubMed
29. Mcdermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in
combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2019;24:749-57. DOI PubMed PMC
30. Choueiri TK, Albiges L, Haanen JBAG, et al. Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus
sunitinib (S) in advanced renal cell carcinoma (aRCC). JCO 2019;37:101. DOI
31. Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.
Science 2018;359:801-6. DOI PubMed PMC
32. Braun DA, Ishii Y, Walsh AM, et al. Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in
renal cell carcinoma. JAMA Oncol 2019;5:1631-3. DOI PubMed PMC
33. Liu XD, Kong W, Peterson CB, et al. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor
resistance in renal carcinoma. Nat Commun 2020;11:2135. DOI PubMed PMC
34. Becerraa MF, Reznik E, Redzematovice A, et al. Comparative genomic profiling of matched primary and metastatic tumors in renal
cell carcinoma maria. Eur Urol Focus 2018;6:986-94. DOI
35. Pignon J, Jegede O, Shukla SA, et al. Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1
blockade in metastatic clear cell renal cell carcinoma (mccRCC). JCO 2019;37:4568. DOI
36. Panda A, de Cubas AA, Stein M, et al. Endogenous retrovirus expression is associated with response to immune checkpoint blockade
in clear cell renal cell carcinoma. JCI Insight 2018;3:121522. DOI PubMed PMC
37. Bui MHT, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell
carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11. PubMed
38. Hakimi AA, Voss MH, Kuo F, et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell
renal cell cancer: data from a randomized phase III trial. Cancer Discov 2019;9:510-25. DOI PubMed PMC
39. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in
patients with papillary renal cell carcinoma. J Clin Oncol 2013;31:181-6. DOI PubMed PMC
40. Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in
patients with metastatic Renal Cell Carcinoma. Clin Cancer Res 2016;22:2445-52. DOI PubMed PMC
41. Voss MH, Hakimi AA, Pham CG, et al. Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit
from mTOR inhibitor therapy. Clin Cancer Res 2014;20:1955-64. DOI PubMed PMC
42. Roldan-Romero JM, Beuselinck B, Santos M, et al; Spanish Oncology Genitourinary Group (SOGUG). PTEN expression and
mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Int J Cancer
2020;146:1435-44. DOI PubMed
43. Dizman N, Lyou Y, Salgia N, et al. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell
carcinoma: comprehensive genomic and transcriptomic analysis. J Immunother Cancer 2020;8:e000953. DOI PubMed PMC
44. Zhu J, Pabla S, Labriola M, et al. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI)
response in metastatic renal cell carcinoma (mRCC). JCO 2019;37:2595. DOI
45. Huang J, Li Z, Fu L, et al. RETRACTED ARTICLE: Comprehensive characterization of tumor mutation burden in clear cell renal cell
carcinoma based on the three independent cohorts. J Cancer Res Clin Oncol 2021;147:1745. DOI PubMed
46. Labriola MK, Zhu J, Gupta RT, et al. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship
to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J Immunother Cancer 2020;8:e000319. DOI PubMed
PMC